Agios Pharmaceuticals
AGIO
163 hedge funds and large institutions have $1.99B invested in Agios Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 68 increasing their positions, 36 reducing their positions, and 25 closing their positions.
92% more call options, than puts
Call options by funds: $60.5M | Put options by funds: $31.6M
89% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 36
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
40% more capital invested
Capital invested by funds: $1.42B → $1.99B (+$568M)
36% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 25
5% more funds holding
Funds holding: 155 → 163 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$32.1M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$25.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$21.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$61.6M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$7.61M |
| 3 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$7.1M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.1M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$1.69M |
AGIO Hedge Fund Activity: Q3 2016 in Review
163 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2016, worth a combined $1.99B — up 40% from $1.42B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new AGIO positions and 25 closed out — a net gain of 9 holders — while 68 added to existing stakes and 36 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $32.1M. The largest seller was Capital World Investors, cutting an estimated $61.6M.
- 163 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2016, up from 155 in Q2 2016.
- Funds reported $1.99B of Agios Pharmaceuticals stock for Q3 2016, up 40% quarter-over-quarter.
- 34 funds opened new Agios Pharmaceuticals positions in Q3 2016 and 25 closed out, a net change of +9 holders.
- The largest Agios Pharmaceuticals buyer in Q3 2016 was Redmile Group, an estimated $32.1M added.
- The largest Agios Pharmaceuticals seller in Q3 2016 was Capital World Investors, an estimated $61.6M sold.
Based on aggregated 13F filings for Q3 2016.